Drugs / Profectus HIV MAG pDNA vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01266616 | Mar 2011 → Oct 2012 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Profectus HIV MAG pDNA vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01266616 ↗ |
| Known as | HIV MAG pDNA vaccine | “HIV MAG pDNA vaccine and sequentially increasing doses of GENEVAX IL-12 pDNA or placebo by IM/EP” NCT01266616 ↗ |
| Modality | Vaccine | “The Profectus Biosciences multiantigen (MAG) HIV-1 DNA vaccine encodes HIV-1 Gag/Pol, Nef/Tat/Vif, and Envelope” PMID 26761518 ↗ Feb 2016 |
| Route | Intramuscular | “is delivered by electroporation combined with intramuscular injection (IM-EP)” PMID 26761518 ↗ Feb 2016 |